Conventional antibody (e.g., monoclonal IgGs) has limitations: high production costs, poor tissue penetration, long serum half-life due to their large sizes (150 kDa) ａnd complex structures, which hinder the widespread use as therapeutics ａnd imaging reagents.

傳統(tǒng)抗體(例如單克隆IgG)存在生產(chǎn)成本高、組織滲透性差、體積大(150 kDa)和結(jié)構(gòu)複雜導(dǎo)致的血清半衰期長(zhǎng)等局限性，阻礙了其作為治療和成像試劑的廣泛應(yīng)用。

Single Domain Antibody (sdAb) is the smallest known antigen-binding fragment. The size of sdAb is one-tenth of conventional antibody. In this respect, sdAb holds a plethora of intrinsic advantages: high affinity, recognition of hidden antigenic sites, improved tissue penetration, ability to trespassing the blood brain barrier, better thermal ａnd chemical stability, high solubility, high modularity, large-scale production, ａnd readily re-formatted to be used across many scientific disciplines.

納米抗體(Single Domain Antibody, sdAb)是已知小的抗原結(jié)合片段，其大小是常規(guī)抗體的十分。此外，納米抗體擁有很多的內(nèi)在優(yōu)勢(shì)：高親和力，對(duì)隱藏抗原位點(diǎn)的識(shí)別，高組織穿透能力，突破血腦屏障的能力，更好的熱和化學(xué)穩(wěn)定性，高溶解性，高模組化，易大規(guī)模生產(chǎn)，易於改造以應(yīng)用於不同用途。

Jotbody adopts a cost-effective ａnd short-cycle workflow for the discovery of sdAb from Camel, Alpaca, Llama (VHH) ａnd Shark (VNAR). Through comprehensive technology platforms ａnd service portfolios, our team is best at discovering unique sdAb candidates to satisfy your specific requirements.

艾美捷Jotbody 采用低成本、短週期的開(kāi)發(fā)流程用於發(fā)現(xiàn)源自駱駝、羊駝和鯊魚(yú)的納米抗體。通過(guò)全面的技術(shù)平臺(tái)和服務(wù)組合，并擅長(zhǎng)發(fā)現(xiàn)獨(dú)特的納米抗體候選分子，以滿(mǎn)足一站式需求。

Jotbody在生物化學(xué)、免疫學(xué)和藥物傳遞域具有強(qiáng)大的研究背景，主要研發(fā)采用低成本、短周期的開(kāi)發(fā)流程，生產(chǎn)源自駱駝、羊駝和鯊魚(yú)的納米抗體候選分子，具有非常大的潛力。艾美捷科技是Jotbody的中國(guó)代理商，為科研工作者提供優(yōu)質(zhì)的產(chǎn)品與服務(wù)。

來(lái)源：https://www.amyjet.com/brand/Jotbody.shtml